Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Radius Health Gained as Much as 20.2% Today

By Maxx Chatsko - May 22, 2017 at 1:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A leading competitor's osteoporosis drug encountered serious side effects in a late stage trial.

What happened

Shares of Radius Health ( RDUS -5.59% ) rose over 20% Monday morning after Amgen ( AMGN 0.96% ) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.

Amgen's failure is Radius Health's gain. The latter gained marketing approval at the end of April for an osteoporosis drug, named Tymlos, which is in the same class as Evenity. It will now have at least a one-year head start on its competitor. As of 12:18 p.m. EDT, the stock had settled to a 6.7% loss and a total market cap of $1.6 billion. Meanwhile, Amgen was down roughly 2.2%, which represents a $2.4 billion hit to its market valuation.

Money raining down around a woman looking at her phone.

Image source: Getty Images.

So what

Both Evenity and Tymlos are anabolic treatments, which means they encourage bone growth, rather than merely preventing bones from becoming more brittle, as prior generation osteoporosis drugs have done. While Eli Lilly ( LLY 0.44% ) was the first to market a drug in this class when Forteo gained marketing approval in 2002, it has faced no competitors despite achieving $1.5 billion in global sales last year, including $770 million in the United States. All of its patents expire by August 2019. 

The news from Amgen means Radius Health could be the lone challenger to Eli Lilly in treating postmenopausal women with osteoporosis at a high risk of fracture. Tymlos was approved in part because it demonstrated an 86% reduction in new spine fractures and a 43% reduction in nonvertebral fractures compared to placebo. Forteo reports reductions of 65% and 53%, respectively. Still, investors should bear in mind that competition from generic formulations of Forteo could weigh on the launch and ultimate success of Tymlos. 

Now what

The osteoporosis market may have lost a key piece of competition after the just-announced Amgen setback. While that could be bad news for patients and drug pricing advocates, the potential arrival of generics and, soon, Radius Health's Tymlos, promise to increase the number of options available to those at risk of serious and even life threatening bone fractures.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Radius Health, Inc. Stock Quote
Radius Health, Inc.
$15.54 (-5.59%) $0.92
Amgen Inc. Stock Quote
Amgen Inc.
$200.80 (0.96%) $1.92
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$249.13 (0.44%) $1.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.